{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:40:29Z","timestamp":1767973229861,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T00:00:00Z","timestamp":1323561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00520-011-1318-2","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T01:48:34Z","timestamp":1323481714000},"page":"2089-2096","source":"Crossref","is-referenced-by-count":15,"title":["Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review"],"prefix":"10.1007","volume":"20","author":[{"given":"David H.","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Tak","family":"Piech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mekr\u00e9","family":"Senbetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy L.","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Stepanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,11]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616\u20131634","journal-title":"J Natl Cancer Inst"},{"key":"1318_CR2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293\u20132306","journal-title":"Eur J Cancer"},{"key":"1318_CR3","first-page":"346","volume":"8","author":"GM Rodgers","year":"2008","unstructured":"Rodgers GM (2008) Managing patients with chemotherapy-induced anemia. Adv Stud Med 8:346\u2013351","journal-title":"Adv Stud Med"},{"key":"1318_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1548-5315(11)70349-7","volume":"6","author":"B Feinberg","year":"2009","unstructured":"Feinberg B, Gilmore J, Gondesen T et al (2009) Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Commun Oncol 6:257\u2013261","journal-title":"Commun Oncol"},{"key":"1318_CR5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1548-5315(11)70353-9","volume":"6","author":"SS Shord","year":"2009","unstructured":"Shord SS, Auerbach M (2009) Treating chemotherapy-induced anemia following the revised labeling for ESAs. Commun Oncol 6:279\u2013282","journal-title":"Commun Oncol"},{"key":"1318_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2007-08-109488","volume":"111","author":"JD Rizzo","year":"2008","unstructured":"Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update. Blood 111:25\u201341","journal-title":"Blood"},{"key":"1318_CR7","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","volume":"23","author":"B Leyland-Jones","year":"2005","unstructured":"Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960\u20135972","journal-title":"J Clin Oncol"},{"key":"1318_CR8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","volume":"362","author":"M Henke","year":"2003","unstructured":"Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255\u20131260","journal-title":"Lancet"},{"key":"1318_CR9","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1592\/phco.28.5supp.1S","volume":"28","author":"RB Arbuckle","year":"2008","unstructured":"Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ (2008) Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care. Pharmacotherapy 28:1S\u201315S","journal-title":"Pharmacotherapy"},{"key":"1318_CR10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","volume":"26","author":"RE Smith Jr","year":"2008","unstructured":"Smith RE Jr, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040\u20131050","journal-title":"J Clin Oncol"},{"key":"1318_CR11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394\u2013403","journal-title":"Br J Haematol"},{"key":"1318_CR12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","volume":"25","author":"JR Wright","year":"2007","unstructured":"Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non\u2013small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027\u20131032","journal-title":"J Clin Oncol"},{"key":"1318_CR13","doi-asserted-by":"crossref","unstructured":"Overgaard J, Hoff CM, Hansen HS et al (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp\u00ae) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)\u2014the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl 5:6LB","DOI":"10.1016\/S1359-6349(07)70099-X"},{"key":"1318_CR14","unstructured":"Oncologic Drugs Advisory Committee briefing document: continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4301b2-02-FDA.pdf . Accessed 15 March 2010"},{"key":"1318_CR15","unstructured":"Background information for Oncologic Drugs Advisory Committee: safety of erythropoiesis-stimulating agents (ESAs) in oncology. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4301b2-01-01-Amgen.pdf . Accessed 15 March 2010"},{"key":"1318_CR16","unstructured":"Decision memo for erythropoiesis-stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). The use of erythropoiesis stimulating agents in cancer and related neoplastic conditions. Available at http:\/\/www.cms.hhs.gov\/mcd\/viewdecisionmemo.asp?id=203 . Accessed 15 March 2010"},{"key":"1318_CR17","unstructured":"Information on erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). Available at http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm109375.htm . Accessed 15 March 2010"},{"key":"1318_CR18","doi-asserted-by":"crossref","first-page":"20595","DOI":"10.1200\/JCO.2007.15.9533","volume":"26","author":"A Naeim","year":"2008","unstructured":"Naeim A, Glaspy J (2008) Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. J Clin Oncol 26:20595","journal-title":"J Clin Oncol"},{"key":"1318_CR19","unstructured":"Burton T, Larholt K, Apgar E et al (2008) Pre- vs. post-National Coverage Determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA). In: American Society of Hematology, 50th Annual Meeting and Exposition, December 6\u20139, 2008, San Francisco, CA"},{"key":"1318_CR20","unstructured":"Centocor Ortho Biotech Products, L.P. (2010) Procrit\u00ae (epoetin alfa) full prescribing information. Centocor ortho Biotech Products, LP, Raritan, NJ"},{"key":"1318_CR21","unstructured":"Amgen Inc. (2010) Aranesp\u00ae (darbepoetin alfa) full prescribing information. Amgen Inc., Thousand Oaks, CA"},{"key":"1318_CR22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","volume":"94","author":"J Vansteenkiste","year":"2002","unstructured":"Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211\u20131220","journal-title":"J Natl Cancer Inst"},{"key":"1318_CR23","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606\u20132617","journal-title":"J Clin Oncol"},{"key":"1318_CR24","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1200\/JCO.2008.19.1130","volume":"27","author":"H Ludwig","year":"2009","unstructured":"Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA (2009) Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 27:2838\u20132847","journal-title":"J Clin Oncol"},{"key":"1318_CR25","doi-asserted-by":"crossref","first-page":"e20627","DOI":"10.1200\/jco.2009.27.15_suppl.e20627","volume":"27","author":"SA Hulnick","year":"2009","unstructured":"Hulnick SA, Hess G, Hill J et al (2009) Erythropoiesis stimulating agent (ESA) administration at Hb <10\u00a0g\/dL for chemotherapy-induced anemia (CIA) following the National Coverage Decision (NCD). J Clin Oncol 27:e20627","journal-title":"J Clin Oncol"},{"key":"1318_CR26","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1200\/jco.2009.27.15_suppl.6611","volume":"27","author":"I Shapira","year":"2009","unstructured":"Shapira I, Raftopoulos H, Gralla RJ et al (2009) The impact of randomized trial results and altered regulatory policies on ESA use, transfusions, and thrombosis: a longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive oncology program. J Clin Oncol 27:6611","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-011-1318-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1318-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T17:03:00Z","timestamp":1639933380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-011-1318-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,11]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s00520-011-1318-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,11]]}}}